
Company valuation, historical trends, and peer comparisons.
According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.21B. This represents a change of -13.76% compared to the average of 2.56B of the last 4 quarters.
The mean historical Enterprise Value of Arcus Biosciences, Inc. over the last ten years is 1.18B. The current 2.21B Enterprise Value has changed 87.05% with respect to the historical average. Over the past ten years (40 quarters), RCUS's Enterprise Value was at its highest in in the June 2026 quarter at 3.85B. The Enterprise Value was at its lowest in in the March 2018 quarter at -51615845.12.
Average
1.18B
Median
1.26B
Minimum
301.77M
Maximum
2.78B
Discovering the peaks and valleys of Arcus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 229.33%
Maximum Annual Enterprise Value = 2.78B
Minimum Annual Increase = -49.54%
Minimum Annual Enterprise Value = 301.77M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 2.45B | 95.70% |
| 2024 | 1.25B | -3.53% |
| 2023 | 1.30B | -7.52% |
| 2022 | 1.40B | -49.54% |
| 2021 | 2.78B | 119.46% |
| 2020 | 1.27B | 229.33% |
| 2019 | 384.71M | 27.48% |
| 2018 | 301.77M | -5.40% |
| 2017 | 319.00M | -9.44% |
The current Enterprise Value of Arcus Biosciences, Inc. (RCUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.67B
5-year avg
1.84B
10-year avg
1.18B
Arcus Biosciences, Inc.’s Enterprise Value is less than ImmunityBio, Inc. (9.25B), less than Denali Therapeutics Inc. (2.77B), greater than Galapagos N.V. (1.82B), less than Cogent Biosciences, Inc. (5.27B), greater than 89bio, Inc. (2.11B), greater than Agios Pharmaceuticals, Inc. (1.77B), less than Viridian Therapeutics, Inc. (2.81B), less than Beam Therapeutics Inc. (2.76B), greater than Ocular Therapeutix, Inc. (931.59M), less than Liquidia Corporation (3.68B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 9.25B | $8.52B | |
| 2.77B | $2.94B | |
| 1.82B | $1.84B | |
| 5.27B | $5.21B | |
| 2.11B | $2.20B | |
| 1.77B | $1.84B | |
| 2.81B | $2.74B | |
| 2.76B | $2.73B | |
| 931.59M | $1.45B | |
| 3.68B | $3.84B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Arcus Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 3-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 5-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
How does the current Enterprise Value for Arcus Biosciences, Inc. (RCUS) compare to its historical average?